Imatinib Sandoz (Imatinib)

Imatinib blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By preventing phosphorylation of these enzymes, it halts downstream signaling that drives malignant cell proliferation, leading to reduced tumor growth and increased cancer cell death.

The dose of Imatinib Sandoz is individualized by the prescribing clinician based on the specific indication, disease stage, patient weight, renal and hepatic function, and any concomitant therapies. No fixed regimen is provided here.

Safety data for Imatinib Sandoz in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, and potential risks to the fetus or infant should be discussed with a healthcare professional before use.

To place an order, submit an enquiry on the Imatinib Sandoz product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first BCR‑ABL tyrosine‑kinase inhibitor approved for CML and remains a standard first‑line option. Newer TKIs such as dasatinib or nilotinib may offer faster molecular responses in some patients, but imatinib’s long‑term safety profile and extensive clinical experience make it a widely used comparator.

Imatinib Sandoz tablets should be stored at ambient temperature below 25 °C, in the original blister or bottle, protected from moisture and direct light. Do not store in bathrooms or near heat sources.

Imatinib Sandoz is taken orally, usually with a glass of water. It can be swallowed with or without food, but patients should follow the prescribing physician’s instructions regarding timing relative to meals.

Serious adverse events include hepatotoxicity, severe neutropenia, and cardiac failure. Patients should report signs of liver dysfunction (jaundice, dark urine), unexplained infections or fever, and symptoms of heart failure such as shortness of breath or swelling of the ankles.

Imatinib Sandoz should be avoided in individuals with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for patients with severe hepatic impairment, uncontrolled cardiac disease, or those receiving contraindicated drug combinations.